Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of LY3526318 in Healthy Male Japanese Participants
NCT05580250Phase 1Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of LY3526318 (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Event(s) at Day 12, Maximum Concentration of Metformin at Day 8 and 6 more. Planned start Nov 2022; status: withdrawn.
02
Drugs
LY3526318
Beyond the preview
Go deeper on NCT05580250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580250.